Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxymetazoline 0.05% · 1 trial · 1 indication
Subjective feeling of nasal congestion will be evaluated by the 100 mm Visual Analog Score (VAS) (0-100 mm): 0 being completely clear and 100 being completely obstructed.
| Arm | Type | Description |
|---|---|---|
| Oxymetazoline HCl 0.05% nasal gel low dose | EXPERIMENTAL | Participants will self-administer oxymetazoline HCl 0.05% nasal gel, once in each nostril. |
| Oxymetazoline HCl 0.05% nasal gel intermediate dose | EXPERIMENTAL | Participants will self-administer oxymetazoline HCl 0.05% nasal gel, once in each nostril. |
| Oxymetazoline HCl 0.05% nasal gel high dose | EXPERIMENTAL | Participants will self-administer oxymetazoline HCl 0.05% nasal gel, once in each nostril. |
| Placebo nasal gel | PLACEBO_COMPARATOR | Participants will self-administer placebo nasal gel, once in each nostril. |
| Name | Type | Description |
|---|---|---|
| Oxymetazoline HCl 0.05% nasal gel | DRUG | Single dose; intranasally, once in each nostril. |
| Placebo nasal gel | DRUG | Single dose; intranasally, once in each nostril. |
Inclusion Criteria: * Male and female participants, age between 18 to 65 years at the time of signing the informed consent. * Participants in good general health per medical evaluation (medical, allergy, and social history; physical and nasal examinations). * Participants who self-report acute nasa...
Oxymetazoline 0.05% is a small molecule being developed for the treatment of nasal congestion and nasal obstruction. It is formulated as a nasal gel and is currently in Phase 2 clinical development. The drug is intended for use in the ear, nose, and throat (ENT) therapeutic area.
Oxymetazoline 0.05% is being developed by Bayer AG, a company listed on the OTC market under the ticker BAYRY. Bayer is conducting clinical trials to evaluate the efficacy and safety of this nasal gel formulation for nasal congestion and obstruction.
Oxymetazoline 0.05% is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, involving 120 participants, to assess how well the drug works and how safe it is.
Oxymetazoline 0.05% has one completed Phase 2 clinical trial, identified as NCT07582328. This study, titled 'A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy Adults,' enrolled 120 healthy adult participants in Canada. The trial was randomized, double-blind, and placebo-controlled.
Yes, Oxymetazoline 0.05% is the same as Oxymetazoline HCl 0.05%. The clinical trial NCT07582328 refers to the drug as Oxymetazoline HCl 0.05% nasal gel, confirming that the hydrochloride salt form is the active ingredient in this formulation.